|

SPOTLIGHT IN FOCUS – The Rise of Psychedelic Therapy



Dr. Zinia Thomas at Radiance Wellness, St. Louis MO – Dr. Zinia Thomas is a psychiatrist whose interest in utilizing the power of psychedelics to promote mental wellness and recovery in her patients with treatment-resistant depression and substance use disorder was peaked long before she began to utilize IV Ketamine as a therapeutic in her own clinic. Dr. Thomas shares her holistic approach and examples of what’s gotten amazing results for her patients.

Bob Parsons is an American entrepreneur and a Marine Corps veteran who suffered all his life from PTSD incurred while serving in Viet Nam. It wasn’t until he read HOW TO CHANGE YOUR MIND by Michael Pollan, that he became inspired by the potential in psychedelics, in conjunction with more mainstream counseling practices, to alleviate suffering from trauma commonly associated with military service. The message continues to be plain and simple, and heard now from voices with no reason to embellish on their beliefs: psychedelics help heal trauma and can save lives.

In May of 2022, NUMINUS WELLNESS sponsored the first in a series of immersive healing sound events entitled MUSIC AS MEDICINE. Olive Kimoto, East Forest, Superposition and Jon Hopkins each shared the stage to engage an audience, present with the intention to heal, with waves of lushly composed ambient and electronic sounds, delivered through high end audio and augmented by evocative visual projections. Numinus CEO Payton Nyquvest and Justin Boreta of Superposition spoke with us about the event, which gloriously exceeded expectations.

#Psychedelics #Numinus #psychiatry

source

Similar Posts

  • Interview With Dr. Gorman

    In this episode of the Psychedelic Spotlight podcast, we speak with Dr. Ingmar Gorman who is the Co-Founder and Lead Trainer at Fluence, and a Principal Investigator for the Multidisciplinary Association for Psychedelic Studies (“MAPS”).ya Health’s Co-Founder and CEO, David Champion, discusses the importance of data and analytics in the growing psychedelic community.

  • Interview With Dr. Steven Mandel

    In this episode of the Psychedelic Spotlight podcast, we have the distinct privilege of speaking with one of the foremost experts in ketamine-assisted therapy, Dr. Steven L. Mandel, Founder and President of Ketamine Clinics Los Angeles.

  • The Psychedelic Sector has Reached “Escape Velocity” | An interview with Cybin’s CEO (CYBN)

    In this episode, James, The Psychedelic Investor, sits down with Doug Drysdale, CEO of Cybin (NYSE: CYBN) for the Psychedelic Spotlight podcast.

    In the interview, the two discuss Cybin’s psychedelic medicines portfolio, and where the psychedelic industry is going in the next few years. Can psychedelics heal mental health?

    The main topic was attempting to answer the question: can psilocybin heal mental health conditions like depression?

    Doug Drysdale spoke on the positive results we have seen in psilocybin for depression clinical trials, such as the Compass Pathways’ psilocybin (comp 360) for treatment-resistant depression phase 2b trial. Despite the apparent benefits of psilocybin, though, Doug Drysdale and Cybin argued that there were 3 core problems with using psilocybin in a therapy setting: the long duration of effect; the onset action period; and the variability of effect.

    Cybin has developed a new version of psilocybin, called CYB-003. CYB-003 has a shorter duration, reaches peak effect quicker, and has less variability in effect between individuals. Plus, it keeps all of the therapeutic benefits of psilocybin and its subjective effects.

    It is important to note that Cybin’s Cyb-003, their next-generation psilocybin, has only been tested in animals up until this point. They intend to start human clinical trials next year.

    James and Doug of Cybin also discussed the other Cybin projects, such as CYB-004, and their development strategy. They also discussed government policy, and whether the psychedelics sector has reaches escape velocity.

    In all, this psychedelic medicines conversation was fascinating and showed Cybin’s dedication towards improving mental health conditions, which are abysmal in the United States right now.

    Enjoy the episode!

    Follow us on social media!
    Instagram: @thepsychedelicinvestor
    Facebook: @thepsychedelicinvestor
    James’ Twitter: @Psy_Invest
    Maria’s Twitter (Producer & Editor): @Psy_Holy
    Want to collaborate? Send us an email at:
    thepsychedelicinvestor@gmail.com

    Music from:
    www.bensound.com

    Video editing: @themyaholy

    DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.
    All of the information in this video is public information that James (The Psychedelic Investor) believes to be reliable but it is not guaranteed to be 100% accurate and as such should not be used as advice. Any opinions or thoughts from James (The Psychedelic Investor) are subject to change.

    #Cybin #Psilocybin #Psychedelics

  • HUGE Studies Released: Psychedelics About to TAKE OVER the Stock market? [ +Horizons ETF UPDATE]

    Hey Psychedelic Investors! There’s been so much news this week that we decided to split “This Week In Psychedelic Stocks” in 2 parts. This segment is entitled “HUGE Studies Released: Psychedelics About to TAKE OVER the Stock market?” for a reason. The News we present will have major implications Psychedelic Stocks like MindMed (MMED /MMEDF/ MMQ), Compass Pathways (CMPS) and more.

    In this episode, there’s lots of news for the psychedelic industry writ large. We’ll start up with three different studies that were released in the first week of April.

    1. The Effects of Treating Depression with Psilocybin
    2. Taking Psychedelics in a Ritual Setting
    3. Microdosing study

    After covering the pertinent aspects of these studies, we’ll take a look at Americans’ ability to buy Horizons’ ETF and finally we’ll give you some updates on some decriminalization efforts.

    So that’s it for This Week in Psychedelic Stocks fellow psychedelic investors!

    I hope you guys found some value in this and I’ll keep you posted for more changes!

    Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news!

    Follow us on social media! 🙌
    Instagram: @psychedelicinvestor
    Facebook: @thepsychedelicinvestor

    If you want to collaborate shoot us an email at: thepsychedelicinvestor@gmail.com

    Music: www.bensound.com
    https://benzinga.grsm.io/jameshallifa
    ​…

    https://benzinga.grsm.io/thepsychedel
    ​…
    ​Timestamps:
    0:00​ – Intro
    1:24 – Effects of Treating Depression with Psilocybin
    4:03 – Effects of Taking Psychedelics in A Ritual Setting
    7:23 – Exploring the relationship between microdosing, personality & emotional insight
    9:36 – Americans May be able to invest in Horizon’s ETF
    11:42 – Progress on California’s bill that would LEGALIZE Possession of Psychedelics
    12:57 – Massachusetts Approves Psychedelics Decimalization

    General thoughts. We’ve been covering decriminalization and legalization efforts for almost two months now and EVERY WEEK, we see a new state or city starting to understand that psychedelics may be beneficial to society and may be able to treat mental illnesses such as depression, anxiety, ADHD, etc. On top of that, every week, we see study after study releasing promising results on the benefits of psychedelics to treat such mental maladies. If this is not proof that the SHROOM BOOM is real, what is? As more studies are released, it’ll only become more clear that psychedelics such as psilocybin, MDMA, DMT, LSD, etc may be able to disrupt a TRILLION dollar industry and us psychedelic investors might as well extract two-fold benefits : a. getting massive returns on investment and b. contributing to make the world a better place.

    DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.

    #MindMed​​​​ ​#psychedelics​​​​ #shroomboom

  • Can Next Generation Psychedelics Treat Mental Illness? | Mindset Pharma | DMT, 5-MEO-DMT

    In today’s episode of the Psychedelic Spotlight Podcast, The Psychedelic Investor sits down with James Lanthier, CEO of Mindset Pharma (CSE: MSET, OTC: MSSTF).

    Mindset Pharma is a psychedelic medicines company working on creating next-generation psychedelics to be used both in a therapy and microdosing setting. 

    Mindset has three variations of psilocybin, the active ingredient in Magic Mushrooms. Two of these are being used in therapy settings, and one will be used for microdosing. Finally, the company has one family of compounds inspired by DMT and 5-MEO-DMT.

    Excitingly, Mindset is moving towards beginning clinical trials in 2022.

    On the day that the interview was recorded, Mindset released some major news; they are teaming up with Otsuka Pharmaceuticals to bring two of their drug families to market. As part of this deal, Mindset will receive $5 million USD upfront, and then Otsuka will also pay for some development costs. 

    In the long term, this deal has great potential for Otsuka. 

    To learn more about Mindset pharma and its stock, listen to the full interview. In it we attempt to answer questions such as:

    Can psychedelics treat mental illnesses such as depression?

    Are next-generation psychedelics better than the originals?

    What is happening in the brain when a person takes psychedelics?

    Enjoy the episode!

    You can find Mindset Pharma trading on the Canadian Securities Exchange under the symbol $MSET and on the American OTC market under the symbol $MSSTF.

    *To learn more about Mindset Pharma visit their website: https://www.mindsetpharma.com/

    #MindsetPharma #DMT #microdosing